Skip to main content
. 2017 Jun 26;38(9):1257–1268. doi: 10.1038/aps.2017.38

Figure 6.

Figure 6

C33(S) could reverse the declining expression of SERCA2a. (A) Cardiac myocytes were transfected with PDE9A siRNA and treated with PE. **P<0.01 vs CON group. #P<0.05 vs PE group. n=4. (B) C33(S) (500 nmol/L and 50 nmol/L) or PF-7943 (2 μmol/L), combined with or without PE treatment. **P<0.01 vs control group. #P<0.05 vs PE group, n=4. (C) The expression of SERCA2a was measured in ISO induced heart failure model treated with C33(S). C33-H: C33(S) 9 mg·kg−1·d−1. C33-M: C33(S) 3 mg·kg−1·d−1. C33-L: C33(S) 1 mg·kg−1·d−1. **P<0.01 vs control group. #P<0.05 vs ISO group. n=3–6 (in vivo). Data were expressed as mean±SEM.